Dot Compliance

Dot ComplianceDot Compliance
Dot Compliance

Dot Compliance

Dot Compliance provides an AI-powered eQMS for life sciences companies to accelerate product delivery and reduce costs.

DR 43Speed 612007Active225Tel Aviv, Israel
Rate

About

Dot Compliance offers the first ready-to-use, AI-powered electronic Quality Management System (eQMS) specifically designed for the Life Sciences industry. Leveraging generative AI capabilities, their eQMS helps medical device manufacturers, biotechnology, and pharmaceutical companies bring products to market faster and more cost-effectively while maintaining regulatory compliance.
Frequently asked

What does Dot Compliance do?

Dot Compliance offers the first ready-to-use, AI-powered electronic Quality Management System (eQMS) specifically designed for the Life Sciences industry. Leveraging generative AI capabilities, their eQMS helps medical device manufacturers, biotechnology, and pharmaceutical companies bring products to market faster and more cost-effectively while maintaining regulatory compliance.

What is Dot Compliance's revenue?

StartupHub estimates Dot Compliance's annual revenue at $40.3M (range $21.4M to $62.0M, 64% confidence), based on comparable companies in the sector.

What is Dot Compliance's valuation?

StartupHub estimates Dot Compliance's effective valuation at $170.9M (range $101.3M to $243.0M, 13% confidence), based on comparable companies in the sector.

How much funding has Dot Compliance raised?

Dot Compliance has raised a total of $41M in funding. The most recent round on record is Series B.

Where is Dot Compliance headquartered?

Dot Compliance is headquartered in Tel Aviv, Israel.

When was Dot Compliance founded?

Dot Compliance was founded in 2007.

What industry does Dot Compliance operate in?

Dot Compliance operates in Life Sciences, Compliance, Quality, MedTech, Biotech, Pharmaceutical.

How many employees does Dot Compliance have?

Dot Compliance has approximately 225 people on record.

HEADCOUNT
225
DOMAIN RATING
43
Comments

No comments yet. Be the first to share your take.